Are Incretin Therapies All Alike? Maximizing Treatment Potential for Type 2 Diabetes Patients in Primary Care
Are Incretin Therapies All Alike? Maximizing Treatment Potential for Type 2 Diabetes Patients in Primary Care
Despite major recent advances in diabetes care, a large proportion of patients do not achieve glycemic control. There is a clear need for treatments that offer effective glucose control while addressing the comorbid factors associated with diabetes, such as obesity and risk of cardiovascular disease, without the risk of hypoglycemia. This is a case-based lecture focusing on the clinical differences between incretin agents and their place in guidelines.
Target Audience
This activity is relevant to physicians, physician assistants, nurses, and other healthcare providers.
Learning Objectives
- Differentiate between incretin-based therapies with respect to important clinical effects beyond glycemic control in patients with type 2 diabetes (T2D)
- Apply clinical practice guidelines for the management of patients with T2D to appropriately and effectively incorporate incretin-based therapy into treatment plans
- Develop T2D treatment plans that meet the individual patient’s therapeutic needs and preference
Additional Information
Faculty Disclosures | ||
Name | Relationship | Company |
Carol H. Wysham, MD Clinical Associate Professor of Medicine University of Washington Section Head, Rockwood Center for Diabetes and Endocrinology Rockwood Clinic Spokane, Washington |
Consultant
Speakers Bureau |
Astra Zeneca, Jansen, Sanofi
Astra Zeneca, Jansen, Novo Nordisk, Sanofi |
Available Credit
- 1.00 AMA PRA Category 1 Credits™